287 related articles for article (PubMed ID: 32633024)
1. Role of aldo-keto reductase family 1 member B1 (AKR1B1) in the cancer process and its therapeutic potential.
Khayami R; Hashemi SR; Kerachian MA
J Cell Mol Med; 2020 Aug; 24(16):8890-8902. PubMed ID: 32633024
[TBL] [Abstract][Full Text] [Related]
2. Aldo-keto reductase family 1 member B1 inhibitors: old drugs with new perspectives.
Liu J; Wen G; Cao D
Recent Pat Anticancer Drug Discov; 2009 Nov; 4(3):246-53. PubMed ID: 19522700
[TBL] [Abstract][Full Text] [Related]
3. Major differences exist in the function and tissue-specific expression of human aflatoxin B1 aldehyde reductase and the principal human aldo-keto reductase AKR1 family members.
O'connor T; Ireland LS; Harrison DJ; Hayes JD
Biochem J; 1999 Oct; 343 Pt 2(Pt 2):487-504. PubMed ID: 10510318
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of an aldo-keto reductase gene signature with prognostic significance in colon cancer via activation of epithelial to mesenchymal transition and the p70S6K pathway.
Demirkol Canlı S; Seza EG; Sheraj I; Gömçeli I; Turhan N; Carberry S; Prehn JHM; Güre AO; Banerjee S
Carcinogenesis; 2020 Sep; 41(9):1219-1228. PubMed ID: 32628753
[TBL] [Abstract][Full Text] [Related]
5. Inhibitor selectivity between aldo-keto reductase superfamily members AKR1B10 and AKR1B1: role of Trp112 (Trp111).
Zhang L; Zhang H; Zhao Y; Li Z; Chen S; Zhai J; Chen Y; Xie W; Wang Z; Li Q; Zheng X; Hu X
FEBS Lett; 2013 Nov; 587(22):3681-6. PubMed ID: 24100137
[TBL] [Abstract][Full Text] [Related]
6. β2-AR regulates the expression of AKR1B1 in human pancreatic cancer cells and promotes their proliferation via the ERK1/2 pathway.
Xiao MB; Jin DD; Jiao YJ; Ni WK; Liu JX; Qu LS; Lu CH; Ni RZ; Jiang F; Chen WC
Mol Biol Rep; 2018 Dec; 45(6):1863-1871. PubMed ID: 30306507
[TBL] [Abstract][Full Text] [Related]
7. The AKR1B1 inhibitor epalrestat suppresses the progression of cervical cancer.
Ji J; Xu MX; Qian TY; Zhu SZ; Jiang F; Liu ZX; Xu WS; Zhou J; Xiao MB
Mol Biol Rep; 2020 Aug; 47(8):6091-6103. PubMed ID: 32761301
[TBL] [Abstract][Full Text] [Related]
8. The Expression and Clinical Significance of Aldo-Keto Reductase 1 Member B1 in Gastric Carcinoma.
Li X; Yang J; Gu X; Xu J; Li H; Qian J; Chen L
DNA Cell Biol; 2020 Jul; 39(7):1322-1327. PubMed ID: 32412859
[TBL] [Abstract][Full Text] [Related]
9. Aldo-Keto Reductase Family 1 Member B10 Inhibitors: Potential Drugs for Cancer Treatment.
Huang L; He R; Luo W; Zhu YS; Li J; Tan T; Zhang X; Hu Z; Luo D
Recent Pat Anticancer Drug Discov; 2016; 11(2):184-96. PubMed ID: 26844556
[TBL] [Abstract][Full Text] [Related]
10. Opposing roles of the aldo-keto reductases AKR1B1 and AKR1B10 in colorectal cancer.
Taskoparan B; Seza EG; Demirkol S; Tuncer S; Stefek M; Gure AO; Banerjee S
Cell Oncol (Dordr); 2017 Dec; 40(6):563-578. PubMed ID: 28929377
[TBL] [Abstract][Full Text] [Related]
11. AKR1B1 promotes basal-like breast cancer progression by a positive feedback loop that activates the EMT program.
Wu X; Li X; Fu Q; Cao Q; Chen X; Wang M; Yu J; Long J; Yao J; Liu H; Wang D; Liao R; Dong C
J Exp Med; 2017 Apr; 214(4):1065-1079. PubMed ID: 28270406
[TBL] [Abstract][Full Text] [Related]
12. Protective Effect of Aldo-keto Reductase 1B1 Against Neuronal Cell Damage Elicited by 4'-Fluoro-α-pyrrolidinononanophenone.
Morikawa Y; Miyazono H; Kamase K; Suenami K; Sasajima Y; Sato K; Endo S; Monguchi Y; Takekoshi Y; Ikari A; Matsunaga T
Neurotox Res; 2021 Aug; 39(4):1360-1371. PubMed ID: 34043181
[TBL] [Abstract][Full Text] [Related]
13. Overexpression and enhanced specific activity of aldoketo reductases (AKR1B1 & AKR1B10) in human breast cancers.
Reddy KA; Kumar PU; Srinivasulu M; Triveni B; Sharada K; Ismail A; Reddy GB
Breast; 2017 Feb; 31():137-143. PubMed ID: 27855345
[TBL] [Abstract][Full Text] [Related]
14. Proteasome inhibitors MG-132 and bortezomib induce AKR1C1, AKR1C3, AKR1B1, and AKR1B10 in human colon cancer cell lines SW-480 and HT-29.
Ebert B; Kisiela M; Wsól V; Maser E
Chem Biol Interact; 2011 May; 191(1-3):239-49. PubMed ID: 21215737
[TBL] [Abstract][Full Text] [Related]
15. AKR1B1 as a Prognostic Biomarker of High-Grade Serous Ovarian Cancer.
Hojnik M; Šuster NK; Smrkolj Š; Sisinger D; Grazio SF; Verdenik I; Rižner TL
Cancers (Basel); 2022 Feb; 14(3):. PubMed ID: 35159076
[TBL] [Abstract][Full Text] [Related]
16. AKR1B1 and AKR1B10 as Prognostic Biomarkers of Endometrioid Endometrial Carcinomas.
Hojnik M; Frković Grazio S; Verdenik I; Rižner TL
Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298614
[TBL] [Abstract][Full Text] [Related]
17. Molecular Interactions and Implications of Aldose Reductase Inhibition by PGA1 and Clinically Used Prostaglandins.
Díez-Dacal B; Sánchez-Gómez FJ; Sánchez-Murcia PA; Milackova I; Zimmerman T; Ballekova J; García-Martín E; Agúndez JA; Gharbi S; Gago F; Stefek M; Pérez-Sala D
Mol Pharmacol; 2016 Jan; 89(1):42-52. PubMed ID: 26487510
[TBL] [Abstract][Full Text] [Related]
18. Bioinformatics Analysis Reveals the Vital Role of AKR1B1 in Immune Infiltration and Clinical Outcomes of Gastric Cancer.
Zhao Z; Hao Z; Zhang Z; Zhan X
DNA Cell Biol; 2023 Jul; 42(7):372-389. PubMed ID: 37285280
[TBL] [Abstract][Full Text] [Related]
19. A Potential Prognostic Biomarker for Glioma: Aldo-Keto Reductase Family 1 Member B1.
Zhao H; Dong X; Huang T; Li X
Comput Intell Neurosci; 2022; 2022():9979200. PubMed ID: 35341178
[TBL] [Abstract][Full Text] [Related]
20. Aldo-keto reductases-mediated cytotoxicity of 2-deoxyglucose: A novel anticancer mechanism.
Zhang SQ; Yung KK; Chung SK; Chung SS
Cancer Sci; 2018 Jun; 109(6):1970-1980. PubMed ID: 29617059
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
